PCOS and infertility: myo-inositol’s benefit for live births remains uncertain

Myo-inositol is used in women with polycystic ovary syndrome (PCOS) and infertility. Yet an updated Cochrane review covering 21 studies and 1,634 participants still cannot establish with confidence whether it increases live births. A possible benefit for clinical pregnancies emerges with in vitro fertilization, but the evidence is of low certainty.

Illustration of myo-inositol studied in the context of PCOS and infertility.
SupplementsEditorial illustration, not study data.

Common practice, but the benefit remains unclear

The use of inositol is based on its proposed effects on insulin sensitivity and ovarian function. This biological rationale is not enough to demonstrate an improved chance of having a child.

The review searched for randomized trials up to November 10, 2025. All participants received usual preconception care. Although the authors searched for several forms of inositol, all studies with relevant data for the selected outcomes involved myo-inositol.

In IVF, a clinical pregnancy does not mean a live birth

Among women undergoing in vitro fertilization, three studies totaling 164 participants suggest that myo-inositol may slightly increase clinical pregnancies compared with no treatment. However, the authors rate the evidence as low certainty.

For live births, the data come from just two studies involving 84 women. The very low certainty of this evidence prevents any conclusion about a benefit. The signal observed for clinical pregnancies therefore does not demonstrate an increase in live births.

The summary provided does not report absolute pregnancy rates in each group. It does not allow the result to be translated into a number of additional pregnancies for a group of treated women.

Other comparisons do not resolve the uncertainty

For ovulation induction or intrauterine insemination, one study involving 120 women provides very low-certainty evidence. Effects on live births, clinical pregnancies and complications remain uncertain.

A comparison with metformin in 102 women undergoing IVF likewise does not establish that myo-inositol is superior. Here too, the certainty of the evidence is very low.

The risks are uncertain too

The results do not allow a robust assessment of effects on miscarriages, multiple pregnancies or ovarian hyperstimulation. Some events were not reported in certain comparisons. These gaps are not evidence of safety.

The practical distinction is clear: this review demonstrates neither that myo-inositol is ineffective nor that it offers a sufficiently reliable benefit for live births. Nor can its conclusions be extended to all commercial inositol formulations.

Limitations to keep in mind

This news article is based solely on the supplied PubMed abstract, without consulting the full text. The review rates the evidence as low to very low certainty, mainly because of indirectness and imprecision. The main analysis includes only five studies. The abstract reports no dedicated funding for the review, but does not allow verification of conflicts of interest or funding for the included trials.

What we can take away

Myo-inositol may support clinical pregnancies with IVF, but its effect on live births and its risks remain uncertain in women with PCOS and infertility.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.